BioSpace News Archive

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, announced that they have entered into a strategic partnership with Genesis Research, combining the expertise and resources of both companies to better serve clients developing new oncology innovations.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has screened the first subject in the ASCEND-NASH clinical trial.

CinCor Pharma, Inc. announced that company management will participate at the following investor conferences: Citi’s 17th Annual BioPharma Conference taking place September 6 - 8, 2022 in Boston, MA and Morgan Stanley’s 20th Annual Healthcare Conference, taking place September 12 - 13, 2022 in New York, NY.

Xtant Medical Holdings, Inc. announced the closing of the first tranche of its previously announced private placement with a select group of accredited investors led by Stavros Vizirgianakis.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), announced today that the U.S. Food & Drug Administration (FDA) has granted tentative approval for Libervant™ (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK), (NASDAQ: CHEKZ), today announced financial results and provided a corporate update for the second quarter and six months ended June 30, 2022.

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced today that Stan Jacot, president and CEO and Pam Haley, CFO, will be participating in two investor conferences during the month of September.

Semler Scientific, Inc. announced, Head of Corporate Communications and Business Strategy, Renae Cormier, will participate in the following investor conferences:

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer of Abata will participate in the following investor conferences.